Similar articles

• Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.

  Neelapu SS, Baskar S, Kwak LW. Neelapu SS, et al. J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2(Suppl 2):R14-9. doi: 10.1007/BF01470994. J Cancer Res Clin Oncol. 2001. PMID: 11768619 Free PMC article.
• Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

  Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Freedman A, et al. J Clin Oncol. 2009 Jun 20;27(18):3036-43. doi: 10.1200/JCO.2008.19.8903. Epub 2009 May 4. J Clin Oncol. 2009. PMID: 19414675 Free PMC article. Clinical Trial.
• Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

  Hurvitz SA, Timmerman JM. Hurvitz SA, et al. Expert Opin Biol Ther. 2005 Jun;5(6):841-52. doi: 10.1517/14712598.5.6.841. Expert Opin Biol Ther. 2005. PMID: 15952914
• Therapeutic lymphoma vaccines: importance of T-cell immunity.

  Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW. Neelapu SS, et al. Expert Rev Vaccines. 2006 Jun;5(3):381-94. doi: 10.1586/14760584.5.3.381. Expert Rev Vaccines. 2006. PMID: 16827622 Review.
• Translational development of vaccination strategies in follicular NHL.

  Sakamaki I, Qin H, Kwak LW. Sakamaki I, et al. Best Pract Res Clin Haematol. 2011 Jun;24(2):295-304. doi: 10.1016/j.beha.2011.03.007. Epub 2011 May 6. Best Pract Res Clin Haematol. 2011. PMID: 21658625 Review.